226 related articles for article (PubMed ID: 20182713)
21. Co-administration of succinylated gelatine with a (99m)Tc-bombesin analogue, effects on pharmacokinetics and tumor uptake.
Liolios CC; Xanthopoulos S; Loudos G; Varvarigou AD; Sivolapenko GB
Nucl Med Biol; 2016 Oct; 43(10):625-34. PubMed ID: 27497631
[TBL] [Abstract][Full Text] [Related]
22. Novel glycated [99mTc(CO)3]-labeled bombesin analogues for improved targeting of gastrin-releasing peptide receptor-positive tumors.
Schweinsberg C; Maes V; Brans L; Bläuenstein P; Tourwé DA; Schubiger PA; Schibli R; García Garayoa E
Bioconjug Chem; 2008 Dec; 19(12):2432-9. PubMed ID: 19053304
[TBL] [Abstract][Full Text] [Related]
23. Spacer site modifications for the improvement of the in vitro and in vivo binding properties of (99m)Tc-N(3)S-X-bombesin[2-14] derivatives.
Fragogeorgi EA; Zikos C; Gourni E; Bouziotis P; Paravatou-Petsotas M; Loudos G; Mitsokapas N; Xanthopoulos S; Mavri-Vavayanni M; Livaniou E; Varvarigou AD; Archimandritis SC
Bioconjug Chem; 2009 May; 20(5):856-67. PubMed ID: 19344122
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis, and biological evaluation of an antagonist-bombesin analogue as targeting vector.
Abd-Elgaliel WR; Gallazzi F; Garrison JC; Rold TL; Sieckman GL; Figueroa SD; Hoffman TJ; Lever SZ
Bioconjug Chem; 2008 Oct; 19(10):2040-8. PubMed ID: 18808168
[TBL] [Abstract][Full Text] [Related]
25. Androgen-regulated gastrin-releasing peptide receptor expression in androgen-dependent human prostate tumor xenografts.
Schroeder RP; de Visser M; van Weerden WM; de Ridder CM; Reneman S; Melis M; Breeman WA; Krenning EP; de Jong M
Int J Cancer; 2010 Jun; 126(12):2826-34. PubMed ID: 19876914
[TBL] [Abstract][Full Text] [Related]
26. Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26.
Mitran B; Varasteh Z; Selvaraju RK; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Rosenström U; Orlova A
Int J Oncol; 2016 May; 48(5):2124-34. PubMed ID: 26983776
[TBL] [Abstract][Full Text] [Related]
27. New [99mTc]bombesin analogues with improved biodistribution for targeting gastrin releasing-peptide receptor-positive tumors.
García Garayoa E; Schweinsberg C; Maes V; Rüegg D; Blanc A; Bläuenstein P; Tourwé DA; Beck-Sickinger AG; Schubiger PA
Q J Nucl Med Mol Imaging; 2007 Mar; 51(1):42-50. PubMed ID: 17372572
[TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo evaluation of 64Cu-labeled DOTA-linker-bombesin(7-14) analogues containing different amino acid linker moieties.
Parry JJ; Kelly TS; Andrews R; Rogers BE
Bioconjug Chem; 2007; 18(4):1110-7. PubMed ID: 17503761
[TBL] [Abstract][Full Text] [Related]
29. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression.
Maddalena ME; Fox J; Chen J; Feng W; Cagnolini A; Linder KE; Tweedle MF; Nunn AD; Lantry LE
J Nucl Med; 2009 Dec; 50(12):2017-24. PubMed ID: 19910427
[TBL] [Abstract][Full Text] [Related]
30. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer.
Zhang X; Cai W; Cao F; Schreibmann E; Wu Y; Wu JC; Xing L; Chen X
J Nucl Med; 2006 Mar; 47(3):492-501. PubMed ID: 16513619
[TBL] [Abstract][Full Text] [Related]
31. Comparative evaluation of the new GRPR-antagonist
Lymperis E; Kaloudi A; Kanellopoulos P; Krenning EP; de Jong M; Maina T; Nock BA
J Labelled Comp Radiopharm; 2019 Aug; 62(10):646-655. PubMed ID: 30963606
[TBL] [Abstract][Full Text] [Related]
32. PEGylation, increasing specific activity and multiple dosing as strategies to improve the risk-benefit profile of targeted radionuclide therapy with 177Lu-DOTA-bombesin analogues.
Däpp S; Müller C; Garayoa EG; Bläuenstein P; Maes V; Brans L; Tourwé DA; Schibli R
EJNMMI Res; 2012 Jun; 2(1):24. PubMed ID: 22681935
[TBL] [Abstract][Full Text] [Related]
33. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
Nock BA; Kaloudi A; Lymperis E; Giarika A; Kulkarni HR; Klette I; Singh A; Krenning EP; de Jong M; Maina T; Baum RP
J Nucl Med; 2017 Jan; 58(1):75-80. PubMed ID: 27493272
[TBL] [Abstract][Full Text] [Related]
34. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
[TBL] [Abstract][Full Text] [Related]
35. Multimodality imaging and preclinical evaluation of 177Lu-AMBA for human prostate tumours in a murine model.
Liu IH; Chang CH; Ho CL; Chiu SP; Lee WC; Chang TJ; Chen LC; Wu YH; Chuang CH; Fu YK; Lee TW
Anticancer Res; 2010 Oct; 30(10):4039-48. PubMed ID: 21036718
[TBL] [Abstract][Full Text] [Related]
36. (99m)technetium-HYNIC(tricine/TPPTS)-Aca-bombesin(7-14) as a targeted imaging agent with microSPECT in a PC-3 prostate cancer xenograft model.
Ananias HJ; Yu Z; Dierckx RA; van der Wiele C; Helfrich W; Wang F; Yan Y; Chen X; de Jong IJ; Elsinga PH
Mol Pharm; 2011 Aug; 8(4):1165-73. PubMed ID: 21699202
[TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo application of radiolabeled gastrin-releasing peptide receptor ligands in breast cancer.
Dalm SU; Martens JW; Sieuwerts AM; van Deurzen CH; Koelewijn SJ; de Blois E; Maina T; Nock BA; Brunel L; Fehrentz JA; Martinez J; de Jong M; Melis M
J Nucl Med; 2015 May; 56(5):752-7. PubMed ID: 25791989
[TBL] [Abstract][Full Text] [Related]
38. PET Probes for Preclinical Imaging of GRPR-Positive Prostate Cancer: Comparative Preclinical Study of [
Kálmán-Szabó I; Szabó JP; Arató V; Dénes N; Opposits G; Jószai I; Kertész I; Képes Z; Fekete A; Szikra D; Hajdu I; Trencsényi G
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077458
[TBL] [Abstract][Full Text] [Related]
39. Application of (99m)Technetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14) SPECT/CT in prostate cancer patients: a first-in-man study.
Ananias HJ; Yu Z; Hoving HD; Rosati S; Dierckx RA; Wang F; Yan Y; Chen X; Pruim J; Lub-de Hooge MN; Helfrich W; Elsinga PH; de Jong IJ
Nucl Med Biol; 2013 Oct; 40(7):933-8. PubMed ID: 23891351
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
